Transient neonatal myasthenia gravis - case report

Authors

  • Rebeka Ribičić KB Sveti Duh
  • Tomislav Ribičić Klinika za dječje bolesti Zagreb
  • Snježana Gverić Klinički bolnički centar "Sestre milosrdnice"

DOI:

https://doi.org/10.13112/pc.1094

Keywords:

MYASTHENIA GRAVIS, NEONATAL; NEONATAL HYPOTONIA; MATERNAL-FETAL EXCHANGE; NEUROMUSCULAR JUNCTION; ACETYLCHOLINE RECEPTOR ANTIBODIES; MUSK ANTIBODIES

Abstract

Transient Neonatal Myasthenia Gravis is a rare, self-limiting condition that affects approximately 10–20% of neonates born to mothers with myasthenia gravis. The disease is mediated by transplacentally transferred maternal autoantibodies, most commonly targeting the acetylcholine receptor (AChR), and less frequently the muscle-specific tyrosine kinase (MuSK), leading to disruption of signal transmission at the fetal neuromuscular junction. Symptoms typically present at birth or within the first four days of life.
  Transient neonatal myasthenia gravis most commonly manifests as weakness of bulbar and limb muscles. Although less frequent, respiratory muscle weakness can occur and may be life-threatening in severe cases. Clinical signs generally resolve within four months, coinciding with the natural clearance of maternal antibodies from the infant’s circulation. Management primarily consists of supportive care. In more severe cases, treatment may include acetylcholinesterase inhibitors, intravenous immunoglobulins, and, rarely, plasmapheresis. The most severe and uncommon forms of the condition can present with multiple congenital arthrogryposis and permanent myopathy. The condition appears more frequently among siblings. Although the pathophysiological mechanisms underlying transient neonatal myasthenia gravis remain poorly understood and biomarker identification is challenging, the risk of disease development can be reduced through optimal maternal disease control. This includes regular prenatal ultrasound monitoring, thymectomy prior to pregnancy, and the administration of immunosuppressive therapy and immunoglobulins, with particular attention to the period between the 13th and 33rd weeks of gestation.

References

1. Lindroos JLV, Bjørk M-H, Gilhus NE. Transient Neonatal Myasthenia Gravis as a Common Complication of a Rare Disease: A Systematic Review. J. Clin. Med. 2024;13(4):1136. doi: 10.3390/jcm13041136.

2. Bodamer OA. Neuromuscular junction disorders in newborns and infants. UpToDate; 2024. Accessed July 20, 2024. https://www.uptodate.com

3. Allen NM, O’Rahelly M, Eymard B, et al. The emerging spectrum of foetal acetylcholine receptor antibody-associated disorders (FARAD). Brain. 2023;146,4233–4246. doi: 10.1093/brain/awad153

4. Iijima S. Clinical and pathophysiologic relevance of autoantibodies in neonatal myasthenia gravis. Pediatr Neonatol. 2021;62(6), 581–590. doi: 10.1016/j.pedneo.2021.05.020.

5. Gilhus NE, Skeie GO, Romi F, Lazaridis K, Zisimopoulou P, Tzartos S. Myasthenia gravis-autoantibody characteristics and their implications for therapy. Nat Rev Neurol. 2016; 12: 259-268. doi: 10.1038/nrneurol.2016.44.

6. Pentšuk N, Van Der Laan JW. An interspecies comparison of placental antibody transfer: New insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res. Part B Dev. Reprod. Toxicol. 2009;86,328–344. doi: 10.1002/bdrb.20201

Published

2025-05-14

Issue

Section

Case Report

How to Cite

Ribičić, R., Ribičić, T., & Gverić, S. (2025). Transient neonatal myasthenia gravis - case report. Paediatria Croatica, 69(2), 115-21. https://doi.org/10.13112/pc.1094

Similar Articles

1-10 of 107

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)